Core Insights - Medtronic has successfully performed the first U.S. commercial surgical case using its FDA-cleared Hugo™ robotic-assisted surgery (RAS) system at Cleveland Clinic, marking a significant milestone in expanding access to minimally invasive surgery [1] Company Developments - The first procedure was a robotic-assisted prostatectomy conducted by Dr. Jihad Kaouk, who emphasized the technology's ability to customize surgical approaches for individual patients [1] - The Hugo RAS system received FDA clearance for urologic surgical procedures in December 2025, and its introduction is part of Medtronic's broader surgical offerings [1] Industry Trends - Urology has seen a high adoption rate of robotic technology, with approximately 80% of urologic abdominal surgeries in the U.S. currently performed with robotic assistance, indicating a strong trend towards robotic-assisted procedures across various specialties [1] - The Hugo RAS system's modular design aims to address operating room scheduling challenges and infrastructure limitations, potentially increasing patient access to the benefits of minimally invasive care [1] Clinical Research - Cleveland Clinic participated in the Expand URO Investigational Device Exemption (IDE) clinical study, which demonstrated that the Hugo RAS system met primary safety and effectiveness endpoints in urologic surgeries [1] - The system is expected to expand its indications into gynecologic and general surgery procedures, including hernia repair, further broadening its application in the surgical field [1]

Group 1 - U.S. stock futures are trading lower on Tuesday morning, indicating a potential decline in market sentiment [1] - Certain stocks are expected to attract investor attention today, although specific names are not mentioned [1] - The article suggests checking premarket coverage for more detailed insights into market movements [1]

Core Viewpoint - The article emphasizes the author's extensive experience in the investment field, particularly in analytics and accounting, highlighting a personal interest in dividend investing [1]. Group 1 - The author holds a master's degree in Analytics from Northwestern University and a bachelor's degree in Accounting [1]. - The author has over 10 years of experience in the investment arena, starting as an analyst and progressing to a management role [1]. - Dividend investing is mentioned as a personal hobby, indicating a focus on income-generating investments [1].

Core Insights - Medtronic has received FDA clearance for the Stealth AXiS™ surgical system, which integrates planning, navigation, and robotics for spine surgery, marking a significant advancement in surgical technology [1] Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries [1] - The company aims to alleviate pain, restore health, and extend life through innovative technologies that address various health conditions [1] Product Details - The Stealth AXiS™ system is designed for spine procedures and has an architecture that supports future cranial and ENT applications, pending further FDA clearance [1] - This system combines familiar navigation workflows with a modular robotic design, allowing for flexibility in deployment according to clinical needs [1] Technological Innovations - A key feature of the Stealth AXiS™ system is LiveAlign™ segmental tracking, which provides real-time visualization of anatomic motion and surgical adjustments, reducing the need for repeated imaging [1] - The system is part of Medtronic's AiBLE™ smart ecosystem, facilitating a seamless flow of information across the surgical continuum [1] Market Position - Medtronic's Cranial and Spinal Technologies division serves over 4 million patients annually with a portfolio of 150 products addressing more than 20 pathologies [1] - The company focuses on building durable platforms that simplify surgical workflows while enabling future expansions across various procedures and specialties [1]

Earnings Report - Medtronic plc is set to release its third-quarter earnings on February 17, with analysts expecting earnings of $1.34 per share, a decrease from $1.39 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $8.9 billion, up from $8.29 billion reported last year [1] - Needham analyst Mike Matson upgraded Medtronic from Hold to Buy, setting a price target of $121 [1] Dividend Information - Medtronic currently offers an annual dividend yield of 2.82%, translating to a quarterly dividend of 71 cents per share, or $2.84 annually [2] - To generate $500 monthly or $6,000 annually from dividends, an investment of approximately $213,159 or around 2,113 shares is required [2] - For a more modest income of $100 per month or $1,200 annually, an investment of $42,672 or around 423 shares is needed [2] Dividend Yield Dynamics - Dividend yield can fluctuate based on changes in both the dividend payment and the stock price [3] - For instance, if a stock with a $2 annual dividend is priced at $50, the yield is 4%, but if the price rises to $60, the yield drops to 3.33% [4] - Conversely, if the stock price falls to $40, the yield increases to 5% [4] - Changes in dividend payments also affect yield; an increase in dividends raises yield if the stock price remains constant [5] Stock Performance - Medtronic's shares fell by 0.2%, closing at $100.88 on Thursday [5]

Earnings Report - Medtronic plc is set to release its third-quarter earnings on February 17, with analysts expecting earnings of $1.34 per share, a decrease from $1.39 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $8.9 billion, up from $8.29 billion reported last year [1] - Needham analyst Mike Matson upgraded Medtronic from Hold to Buy, setting a price target of $121 [1] Dividend Information - Medtronic currently offers an annual dividend yield of 2.82%, translating to a quarterly dividend of 71 cents per share, or $2.84 annually [2] - To generate $500 monthly or $6,000 annually from dividends, an investment of approximately $213,159 or around 2,113 shares is required [2] - For a more modest income of $100 per month or $1,200 annually, an investment of $42,672 or around 423 shares is needed [2] Dividend Yield Dynamics - Dividend yield can fluctuate based on changes in both the dividend payment and the stock price [3] - For instance, if a stock with a $2 annual dividend is priced at $50, the yield is 4%, but if the price rises to $60, the yield drops to 3.33% [4] - Conversely, if the stock price falls to $40, the yield increases to 5% [4] Impact of Dividend Changes - Changes in dividend payments directly affect the yield; an increase in dividends raises the yield if the stock price remains constant, while a decrease lowers it [5] - Medtronic's shares fell by 0.2% to close at $100.88 on Thursday [5]

Core Insights - Becton Dickinson and Co. (BDX) is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents, operating through three segments: BD Medical, BD Life Sciences, and BD Interventional [1] Financial Performance - On February 10, 2026, BDX executed a stock split with a ratio of 125 for 159, aimed at making shares more affordable [2][4] - BDX reported first-quarter 2026 adjusted earnings of $2.91 per share, exceeding the consensus estimate of $2.81, with sales reaching $5.25 billion, slightly above the expected $5.15 billion [2][4] Strategic Changes - BDX is undergoing significant changes, including the separation of its Biosciences and Diagnostic Solutions businesses and a combination with Waters Corporation [3] - The company has lowered its fiscal 2026 adjusted earnings guidance from a range of $14.75-$15.05 per share to $12.35-$12.65 per share, compared to the consensus of $14.72, indicating a transition year according to RBC Capital Markets [3] Stock Performance - BDX's stock is currently priced at $180.62, reflecting an increase of 5.21% or $8.94, with fluctuations between a low of $170.67 and a high of $181.98 during the trading day [3] - Over the past year, BDX has reached a high of $185.02 and a low of $127.59, with a market capitalization of approximately $51.44 billion and a trading volume of 4,441,319 shares on the NYSE [3]

Core Viewpoint - Medtronic plc will announce its financial results for the third quarter of fiscal year 2026 on February 17, 2026, following the end of the quarter on January 23, 2026 [1] Group 1: Financial Reporting - A video webcast discussing the financial results will begin at 7:00 a.m. CST on the announcement day [1] - A news release containing summary financial information will be issued at approximately 5:45 a.m. CST [1] - A replay and transcript of the prepared remarks will be available within 24 hours of the webcast [1] Group 2: Company Overview - Medtronic is headquartered in Galway, Ireland, and is a leading global healthcare technology company [1] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies and therapies [1] - Medtronic's mission is to alleviate pain, restore health, and extend life, focusing on innovative solutions in various medical fields [1]

Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.33 per share, a decline of 4.3% year-over-year, with revenues projected at $8.9 billion, reflecting a 7.3% increase compared to the previous year [1] Revenue Estimates - Analysts estimate 'Net Sales- World Wide Revenue- Cardiovascular' to be $3.37 billion, indicating a year-over-year increase of 10.8% [4] - 'Net Sales- World Wide Revenue- Neuroscience' is projected to reach $2.59 billion, reflecting a 5.3% increase year-over-year [4] - 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' is expected to be $1.32 billion, a 6% increase from the prior year [5] - 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' is forecasted at $505.68 million, indicating a 6.2% year-over-year change [5] U.S. Revenue Estimates - 'Net Sales- U.S. Revenue' is anticipated to be $4.53 billion, suggesting a 6.9% increase year-over-year [6] - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is projected at $342.56 million, reflecting a 4.8% increase [6] International Revenue Estimates - 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' is expected to reach $338.62 million, indicating a 10.3% year-over-year change [6] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is projected at $335.35 million, reflecting a 7.1% increase [7] - 'Net Sales- ROW- Cardiovascular- Cardiac Rhythm & Heart Failure' is expected to be $826.64 million, indicating a 7.4% increase [8] - 'Net Sales- ROW- Diabetes' is projected at $522.47 million, reflecting a significant 14.3% increase from the previous year [8] - The consensus estimate for 'Net Sales- ROW- Cardiovascular' stands at $1.77 billion, indicating an 8.5% year-over-year change [8] Stock Performance - Medtronic shares have shown a return of +5.2% over the past month, outperforming the Zacks S&P 500 composite, which has seen a -0.3% change [9]

RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--Applied Medical Prevails in Antitrust Jury Trial Against Medtronic. ...